Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
Last trade$59.73
Day change-$0.295 (-0.49%)
Day range$59.16 – $60.36
Volume86,734
Market cap$2.03B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.03B
Price / earnings
33.91×
Price / book
32.18×
Price / sales
1.79×
EV / sales
2.73×
EV / EBITDA
8.57×
Profitability
Earnings per share
$1.77
Return on assets
3.98%
Return on equity
94.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
18.18×
Current ratio
1.48×
Quick ratio
1.05×
Cash ratio
0.24×
Cash flow
Price / cash flow
11.23×
Price / free cash flow
16.54×
Free cash flow
$122.6M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NGVT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$305.1M
$314.1M
$258M
$255.1M
$333.1M
$331.5M
$247.9M
$263.3M
Cost of revenue
$172.3M
$175.1M
$141.6M
$167.3M
$199.2M
$203.7M
$136M
$163.4M
Gross profit
$132.8M
$139M
$116.4M
$87.8M
$133.9M
$127.8M
$111.9M
$99.9M
Selling, general and administrative
$38.1M
$39M
$40.7M
$41.6M
$44.1M
$43.6M
$41.9M
$38.3M
Research and development
$8.3M
$6.1M
$6.7M
$7.4M
$7M
$7M
$7M
$6.5M
Total operating expenses
$50.4M
$74.1M
$70.3M
$161M
$53.3M
$245.8M
$54.9M
$54.9M
Operating income
$82.4M
$64.9M
$46.1M
-$73.2M
$80.6M
-$118M
$57M
$45M
Interest expense
-$13.5M
-$14.2M
-$15.9M
-$78.3M
-$18.4M
-$18.6M
-$19.4M
-$97.8M
Income before taxes
$68.9M
$50.7M
$30.2M
-$105.4M
$62.2M
-$136.6M
$37.6M
$24.1M
Income taxes
$17.8M
$10.9M
$6.8M
-$26.6M
$21.4M
$4.8M
$8.5M
$4.5M
Net income
$49.3M
$35.3M
$59.8M
-$84.6M
$43.5M
-$146.5M
$20.5M
$16.6M
Net income attributable to common shareholders
$49.3M
$35.3M
$59.8M
-$84.6M
$43.5M
-$146.5M
$20.5M
$16.6M
EBITDA
$103.5M
$120.7M
$69.3M
$66.7M
$109.6M
$98.6M
$83.8M
$80.3M
Basic earnings per share
$1.44
$1.02
$1.70
-$2.37
$1.20
-$4.02
$0.56
$0.46
Diluted earnings per share
$1.41
$1.00
$1.66
-$2.43
$1.18
-$4.02
$0.56
$0.46
Recent news
Company coverage with links to the original publishers.
Ingevity (NGVT) reported Q3 2026 earnings of $1.63 per share, beating consensus estimates of $1.56, with revenues of $305.1 million slightly exceeding expectations. However, the company received a Zacks Rank #3 (Hold) rating due to mixed estimate revision trends, suggesting near-term performance in line with the market. The stock has outperformed the S&P 500 by 13.8% year-to-date.
Ashland reported quarterly earnings of $1.12 per share, missing consensus estimates of $1.30 and delivering a -13.85% earnings surprise. Revenues also fell short of expectations at $498 million. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions, though it has outperformed the S&P 500 by 26.5% year-to-date. Peer company Ingevity is expected to report results on November 4 with anticipated earnings of $1.56 per share, representing 19.1% year-over-year growth.
Ingevity Corporation (NGVT) reported Q2 adjusted EBITDA of $115 million, up from $101 million year-over-year, driven by higher pricing, favorable product mix, and increased volumes. The company raised its 2026 adjusted EBITDA guidance to $380-$400 million and adjusted EPS outlook to $5-$5.45. NGVT stock has gained 26.3% over the past year and trades at a forward P/S multiple of 2.1, below the industry average of 2.45X.
Ingevity Corporation (NGVT) shares have gained 33.9% over the past year driven by portfolio transformation, strategic divestitures, and disciplined capital allocation. The company is focusing on high-return markets and targeting $300 million in share repurchases through 2027. However, challenges include weakness in the APT business segment, macroeconomic uncertainties, and softer North American auto production forecasts. NGVT carries a Zacks Rank #3 (Hold) rating.
Ingevity Corporation (NGVT) shares have gained 30.6% over the past year, outperforming its industry. The company's portfolio optimization through divestitures and acquisitions, combined with improved cash flow generation and debt reduction to 2.5X leverage, has boosted investor confidence. NGVT is pursuing growth opportunities in PFAS filtration, biofuels applications, and capacity expansions while planning a $300 million share repurchase program through 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.